Autres langues IN8bio, Inc.

Actions

INAB

US45674E1091

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 03/05/2024			Varia. 5j.	Varia. 1 janv.
1 ^USD	-1,96%		-3,85%	-27,54%

30/04	In8bio, Inc. Administre le premier patient de l'essai clinique de phase 2 de l'INB-400 dans le glioblastome nouvellement diagnostiqué	CI
10/04	Les plus fortes hausses du prémarché	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma	30/04
In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma	30/04
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene and Cell Therapy 2024 Annual Meeting	25/04
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting	24/04
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference	16/04
Top Premarket Gainers	10/04
North American Morning Briefing: Traders Await the CPI Report	10/04
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024	09/04
IN8bio, Inc. Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024	09/04
IN8bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights	14/03
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024	05/03
IN8bio, Inc. to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024	05/03
IN8bio to Present at Upcoming Investor Conferences	26/02
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology	14/02
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology	14/02
IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals	04/01
IN8bio, Inc. announced that it has received $14.442298 million in funding from Bios Equity Partners LP	28/12
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	12/12
Top Premarket Gainers	12/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues IN8bio, Inc.

Actions

INAB

US45674E1091

Autres langues

Filtres